Pharmacokinetic modeling of tumor bioluminescence implicates efflux, and not influx, as the bigger hurdle in cancer drug therapy

Cancer Research

Volumn 71, Issue 3, 2011, Pages 686-692

  Sim, Hoon ^a   Bibee, Kristin ^b   Wickline, Samuel ^b   Sept, David ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LUCIFERIN;

ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; BIOLUMINESCENCE IMAGING; CANCER SIZE; CLINICAL EVALUATION; DRUG TRANSPORT; DRUG TUMOR LEVEL; DRUG UPTAKE; FEMALE; HUMAN; IMAGING SYSTEM; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIMULATION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; FEMALE; FIREFLY LUCIFERIN; LUCIFERASES, FIREFLY; LUMINESCENT MEASUREMENTS; MELANOMA, EXPERIMENTAL; MICE; MODELS, BIOLOGICAL; PHARMACOKINETICS; TRANSFECTION;

EID: 79551530743     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-2666     Document Type: Article

References (17)

1. Chung E, Yamashita H, Au P, Tannous BA, Fukumura D, Jain RK. Secreted Gaussia luciferase as a biomarker for monitoring tumor progression and treatment response of systemic metastases. PLoS One 2009;4:e8316.
2. El Hilali N, Rubio N, Blanco J. Noninvasive in vivo whole body luminescent analysis of luciferase labelled orthotopic prostate tumours. Eur J Cancer 2004;40:2851-8.
3. Jenkins DE, Oei Y, Hornig YS, Yu SF, Dusich J, Purchio T, et al. Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis. Clin Exp Metastasis 2003; 20:733-44.
4. Keyaerts M, Verschueren J, Bos TJ, Tchouate-Gainkam LO, Peleman C, Breckpot K, et al. Dynamic bioluminescence imaging for quantitative tumour burden assessment using IV or IP administration of Dluciferin: effect on intensity, time kinetics and repeatability of photon emission. Eur J Nucl Med Mol Imaging 2008; 35:999-1007.
5. Paroo Z, Bollinger RA, Braasch DA, Richer E, Corey DR, Antich PP, et al. Validating bioluminescence imaging as a high-throughput, quantitative modality for assessing tumor burden. Mol Imaging 2004; 3:117-24.
6. Rettig GR, McAnuff M, Liu D, Kim JS, Rice KG. Quantitative bioluminescence imaging of transgene expression in vivo. Anal Biochem 2006;355:90-4.
7. Wurdinger T, Badr C, Pike L, de Kleine R, Weissleder R, Breakefield XO, et al. A secreted luciferase for ex vivo monitoring of in vivo processes. Nat Methods 2008;5:171-3.
8. Thorne SH, Contag CH. Using in vivo bioluminescence imaging to shed light on cancer biology. Proc IEEE 2005;93:750-62.
9. Cui K, Xu X, Zhao H, Wong ST. A quantitative study of factors affecting in vivo bioluminescence imaging. Luminescence 2008;23:292-5.
10. Klerk CP, Overmeer RM, Niers TM, Versteeg HH, Richel DJ, Buckle T, et al. Validity of bioluminescence measurements for noninvasive in vivo imaging of tumor load in small animals. Biotechniques 2007;43:7-13, 30.
11. Rehemtulla A, Stegman LD, Cardozo SJ, Gupta S, Hall DE, Contag CH, et al. Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. Neoplasia 2000;2:491-5.
12. Uluckan O, Eagleton MC, Floyd DH, Morgan EA, Hirbe AC, Kramer M, et al. APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in mice. J Cell Biochem 2008;104:1311-23.
13. Available from: http://septlab.engin.umich.edu/NanoPK/.
14. Available from:http://www.r-project.org.
15. Brutkiewicz S, Mendonca M, Stantz K, Comerford K, Bigsby R, Hutchins G, et al. The expression level of luciferase within tumour cells can alter tumour growth upon in vivo bioluminescence imaging. Luminescence 2007;22:221-8.
16. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure-an obstacle in cancer therapy. Nat Rev Cancer 2004;4:806-13.
17. Aukland K, Reed RK. Interstitial-lymphatic mechanisms in the control of extracellular fluid volume. Physiol Rev 1993;73:1-78. (Pubitemid 23065433)